Navigation Links
Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
Date:8/6/2008

portant biological activity. This dosing regimen is being used in DEFEND. For more information on DEFEND, please see http://www.DefendAgainstDiabetes.com.

Tolerx Collaboration with GlaxoSmithKline

In October 2007, Tolerx and GlaxoSmithKline (GSK) entered into a global alliance to develop and commercialize otelixizumab in numerous indications, including type 1 diabetes. Under the terms of the agreement, Tolerx is responsible for conducting the Phase 3 clinical program for type 1 diabetes in the US and if successful, for submitting the biologics license application (BLA) to the FDA. Tolerx has the option to co-promote otelixizumab in type 1 diabetes in the US with GSK while GSK has exclusive rights to develop and commercialize otelixizumab in all other indications worldwide, including pediatric type 1 diabetes.

About Tolerx

Tolerx is a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases. Tolerx currently has two antibodies in clinical development: otelixizumab and a modified version of TRX1, MTRX1011A. MTRX1011A is a humanized anti-CD4 monoclonal antibody being developed in collaboration with Genentech, Inc. Tolerx is also engaged in preclinical development of new monoclonal antibody product candidates that engage the body's immune system and promote and enhance immune responses. These antibodies are being assessed for potential benefit in the treatment of cancer, chronic viral diseases, and as an adjunct to vaccines. For more information, please visit http://www.tolerx.com.

Tolerx Forward-Looking Statements

This press release contains certain statements that are preceded by, followed by, or that include the words "will evaluate," "will," "look forward," "believe," and "has the potential to," or similar expressions or the negation thereof. Such stateme
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
2. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
3. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
4. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
9. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
10. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , November 26, 2014 Investor-Edge ... VVUS ), Horizon Pharma PLC (NASDAQ: ... and Johnson (NYSE: JNJ ), and Theravance Inc. ... companies can be accessed at: http://investor-edge.com/register . ... 4,758.25, up 0.07%, the Dow Jones Industrial Average edged 0.02% ...
(Date:11/26/2014)... SHANGHAI , Nov. 26, 2014  CARsgen, a ... (CAR-T) cell immunotherapy to treat a variety of cancers, ... led by BVCF, a China -based ... an immunotherapy company focused on the development of new ... collaboration with Shanghai Cancer Institute and Shanghai Renji Hospital, ...
(Date:11/26/2014)... N.C. , Nov. 25, 2014  At the ... Antonio this October, KaVo Kerr Group was ... Technology Expo, offering attendees the opportunity to see and ... well-respected key opinion leaders deliver lectures on the latest ... Group products include the new DEXIS CariVu Caries Detection ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5CARsgen Completes Series A Financing 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3
... , Jan. 29 EP Global Communications, Inc. ... ), the parent company of Exceptional Parent ( EP ) ... has joined the EPGL Advisory Board. Dr. DeFelice is one of the ... term "nutraceutical."  , "This addition to our team of experts will ...
... , PITTSBURGH , Jan. 29 ... subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. ... Application (ANDA) for Polyethylene Glycol 3350 and Electrolytes for Oral ... , Polyethylene Glycol 3350 and Electrolytes for Oral Solution ...
Cached Medicine Technology:EP Global Communications, Inc. Welcomes Stephen DeFelice, MD, to Advisory Board 2EP Global Communications, Inc. Welcomes Stephen DeFelice, MD, to Advisory Board 3Mylan Receives Approval for Generic Version of GoLytely(R) 2
(Date:11/28/2014)... Australia (PRWEB) November 28, 2014 ... undergone healthy growth over the past five years. ... increasing acceptance of therapies that are either alternative ... treatments. According to IBISWorld industry analyst David Whytcross, ... ageing population and growing private health insurance membership.” ...
(Date:11/28/2014)... Celebration can quickly turn to tragedy if popular ... Over the last decade, more than 141 serious ... using turkey fryers, according to the U.S. Consumer Product ... patient who tried to deep fry the turkey indoors, ... Dr. Arthur Sanford, a burn surgeon at Loyola University ...
(Date:11/28/2014)... 28, 2014 Not only is the ... free of petroleum, parabens and other cancer-causing agents, but ... research, education and awareness programs that help in the ... owners have raised an incredible, record-breaking contribution of $30,000 ... sales of the Sweet Red Rose Whip Moisturizer and ...
(Date:11/28/2014)... 2014 Earlier in the year, ... hugely popular, 2014 MTV Video Music Awards broadcasted ... ground-breaking celebrity centered television advertisements directed at 11.9 ... were estimated by Entertainment Weekly and ... spotlight on celebrities photographed by paparazzi smoking. In ...
(Date:11/28/2014)... November 28, 2014 A newly released ... an overview of the influenza virus that will soon be ... , The article begins with a brief explanation of ... symptoms. It reminds families that children under the age of ... from chronic diseases, such as heart and lung diseases, asthma, ...
Breaking Medicine News(10 mins):Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 2Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 4Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 5Health News:How Flu Vaccines Can Impact Families Is Discussed in New Article from Community Health Center of Snohomish County 2
... Memory,Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced ... composition of matter patent,protection for a series of ... R4996/MEM 63908, which are both being developed,in partnership ... such as,Alzheimer,s disease and cognitive impairment associated with ...
... people worship felines,like pharos; dog people talk to hounds ... really are different -- in marital status, economic,standing and ... that there are some interesting differences,between cat owners and ... American Veterinary Medical Association (AVMA). "Our surveys show,that single ...
... in the market for specialty needles is determined by growing demand ... is projected to reach $3.7 billion by the year 2015. ... ... The market for disposable medical products such as syringes, disposable needles, ...
... solely as disease agents -- now are being used ... these so-called oncolytic viruses stem from their potential to ... a way of controlling the viruses behind potential cancer ... microRNAs to restrict them to specific tissues. The microRNAs ...
... Consulting Service is quickly becoming the nation’s leader in ... in 2008 and has already achieved six Joint Commission certifications ... Consulting Service assures agencies understand and meet the healthcare standards ... ...
... association says cooling body, checking arteries lowers risk of further ... heart beating again is only the first step in saving ... shows. , An advisory, published in the Oct. 23 issue ... more quickly after resuscitation or risk the losing the patient ...
Cached Medicine News:Health News:Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908 2Health News:Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908 3Health News:Cat People vs. Dog People ... They Really are Different 2Health News:Special Purpose Needles Market to Reach $3.7 Billion by 2015, According to New Report by Global Industry Analysts, Inc 2Health News:Special Purpose Needles Market to Reach $3.7 Billion by 2015, According to New Report by Global Industry Analysts, Inc 3Health News:MicroRNAs make for safer cancer treatments 2Health News:New Joint Commission Consulting Service by NurseTesting Grows Fast as Staffing Agencies Seek Joint Commission Certification 2Health News:New Joint Commission Consulting Service by NurseTesting Grows Fast as Staffing Agencies Seek Joint Commission Certification 3Health News:Speedy Care After Heart Attack Key to Survival 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: